[1] 刘坤,王海江,孙振强,等. 胃癌组织HER-2和VEGF及EGFR表达临床意义研究[J]. 中华肿瘤防治杂志,2015, 24(10):781-785. [2] 王春艳. EGFR 和 VEGF 联合检测对评估乳腺癌淋巴结转移的意义[J]. 中国实验诊断学,2015,19(3):440-442. [3] 朱建峰,胥荣,李霞,等. EGFR和VEGF在乳腺癌中的表达及意义分析[J]. 右江民族医学院学报,2014,36(4):588-588. [4] 余文杰,沈孝坤. VEGF、EGFR和Ki-67在青年乳腺癌中的表达及与临床病理分期的关系[J]. 中国现代医生,2014, 52(2):26-29. [5] 邱梅婷,秦松树,覃天,等. 血清细胞因子及受体在乳腺癌病情及预后判断中的价值[J]. 山东医药,2014,54(36):14-17. [6] SOS M L,KOKER M,WEIR B A,et al. PTEN loss contributes to erlotinib resistance in egfr-mutant lung cancer by activation of Akt and EGFR[J]. Cancer Research,2009,69(8):3256- 3261. [7] 罗赵鑫,陈仰新,罗先桃,等. VEGF、EGFR、Ki-67及P53的表达与大肠癌浸润转移的相关性[J]. 中国热带医学,2015,15(11):1369-1371. [8] 孟谊,杨杨,樊祥山,等. VEGF、EGFR 的表达与非小细胞肺癌生物学行为的相关性[J]. 现代肿瘤医学,2015,23(5):633-636. [9] MISALE S,ARENA S,LAMBA S,et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer[J]. Science Translational Medicine,2014,6(224):1439-1441. [10] ISHAK R S,AAD S A,KYEI A,et al. Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors[J]. Critical Reviews in Oncology/hematology,2014,90(2):152-164. [11] KARALI E,BELLOU S,STELLAS D,et al. VEGF signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress[J]. Molecular Cell,2014,54(4):559-572. [12] 汪巧,胡向阳,张晓亮,等. Survivin、VEGF、EGFR在甲状腺乳头状癌中的表达及意义[J]. 安徽医科大学学报,2016,51(3):442-446. [13] 吴婧婧,顾康生. 小肠腺癌患者中MMP-9、Ki-67、EGFR和VEGF的表达与临床特征及预后的相关性研究[J]. 安徽医科大学学报,2013,48(6):647-651.